INVO Bioscience, Inc. - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on May 30, 2023, covering the event date of May 23, 2023. The Company is incorporated in Nevada and its common stock is registered on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a regulatory compliance issue regarding stockholders' equity.
Material Changes and Events
- Delisting Notice: On May 23, 2023, the Company received notice from Nasdaq that its common stock is subject to delisting from The Nasdaq Global Market.
- Reason for Notice: The Company failed to meet the $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) as of May 22, 2023.
- Previous Extension: Nasdaq had previously granted an extension to evidence compliance through May 22, 2023, which the Company was unable to satisfy.
Outlook, Management Commentary, and Risks
Management plans to timely request a hearing before the Nasdaq Hearings Panel. This request will stay further delisting action until the hearing process concludes and any potential extension expires. During the hearing, the Company intends to present a plan to regain compliance and request continued listing pending compliance. Management explicitly states there can be no assurance that the Panel will grant the request or that the Company will evidence compliance within any granted extension.
Key Facts for Investor Verification
- Verify the Company's current stockholders' equity balance to assess the gap against the $2.5 million Nasdaq requirement.
- Monitor the status of the hearing request and the scheduled date with the Nasdaq Hearings Panel.
- Review any subsequent filings for the specific plan to regain compliance presented to Nasdaq.
- Check for any updates on the Company's ability to secure an extension or alternative listing status.